98 filings
Page 4 of 5
6-K
q113y2a3
18 Oct 22
Report of Foreign Private Issuer
3:57pm
6-K
9lo16oexowvbul
29 Sep 22
Interim Condensed Financial Statements
2:33pm
6-K
5dorllgd
8 Sep 22
Notice of Annual and Extraordinary General Meeting of Shareholders
4:01pm
6-K
y3h s4jz3sx6qh80qnv
7 Sep 22
Report of Foreign Private Issuer
9:29am
6-K
7srmm3g 2m
11 Aug 22
Inspira™ Technologies Reports Second Quarter 2022 Financial Results
10:07am
6-K
39f jx6pk7yv
10 Aug 22
Report of Foreign Private Issuer
4:01pm
6-K
rcyrzl4xoq cqzmv9a
8 Aug 22
Copyright © 2018 - 2022 Inspira Technologies OXY B.H.N. LTD., All rights reserved August 2022 Investor Presentation
9:17am
6-K
rfiky6sq i29mccnha
11 Jul 22
Report of Foreign Private Issuer
9:29am
6-K
72jxe36bnivl6rr5 m8
7 Jul 22
The agreement signed with Glo-Med Networks for the potential deployment of HYLA™ Blood Sensors over a 3-year period, subject to regulatory approvals
9:16am
6-K
nktmgh
6 Jul 22
HYLA™ blood sensor intends to reduce the need for actual blood samples to be taken from patients
9:07am
6-K
ggvmoryzovlf gesv9hu
19 May 22
Inspira™ Technologies Announces First Quarter 2022 Financial Results
9:05am
6-K
mcb 0qgmdhoaohs
6 Apr 22
Inspira Technologies Announces Deployment Agreement in the Israeli Market to Target $15M
9:25am
6-K
n7e1 py7vajwv
31 Mar 22
Inspira Technologies Releases Q4 & FY2021 Financial Results
4:08pm
6-K
qzss3lddgjzic
3 Feb 22
Inspira Technologies Appointed an Expert in the Field of Artificial Lung as the New Chief Technology Officer (CTO) - Daniella Yeheskely-Hayon PhD
9:06am
6-K
wclone gg5w
1 Feb 22
Report of Foreign Private Issuer
8:58am
6-K
cfwnlfzsktzc 821
31 Jan 22
Inspira Technologies Signs a Strategic Agreement in the U.S. to
9:06am
6-K
95fxixu
28 Jan 22
Inspira Technologies Has Listed an FDA Class I 510(k) Exempt component of the ART system
7:36am
6-K
o63ee go8nfjy7q1
19 Jan 22
Report of Foreign Private Issuer
4:03pm
6-K
cww 5z0re
6 Jan 22
Report of Foreign Private Issuer
6:47am
6-K
47jep7 6pgg
20 Dec 21
Report of Foreign Private Issuer
4:05pm